Zhejiang DiAn Diagnostics Co

First-half 2026 reports from in vitro diagnostics companies listed on the STAR Market show sharp divergence, with Autobio Diagnostics, Biotest Biotech and Orient Gene posting lower net profit while Rendu Biotechnology saw a surge. Autobio Diagnostics' first-half revenue and net profit fell 8.77% and 61.48% respectively, to 392 million yuan and 51 million yuan. Second-quarter revenue and net profit dropped 11.11% and 55.58% year on year, which the company attributed to intensifying industry competition, foreign exchange losses and higher research and development expenses. Orient Gene and Biotest Biotech grew revenue but not profit. Orient Gene's net loss widened to 222 million yuan, down 36.26% year on year, while Biotest Biotech swung from profit to a loss of 16.55 million yuan, plunging 233.46% year on year. Both cited US dollar exchange losses. Rendu Biotechnology's revenue edged down 2.22% to 79.44 million yuan, but net profit attributable to the parent surged 369.86% year on year to 9.58 million yuan, and non-recurring net profit turned positive, mainly thanks to cost reduction and efficiency gains. Selling, administrative and research and development expenses fell 11.86%, 10.10% and 21.98% respectively. In addition, companies such as YHLO Biotech, HOB Biotech and Dian Diagnostics also achieved net profit growth, with Dian Diagnostics' net profit soaring 2,160% to 232 million yuan. However, for some companies the improvement in profit was driven mainly by cost reduction and efficiency gains and a narrowing of credit impairment losses. The industry remains in a deep adjustment cycle, with centralised procurement, medical insurance cost controls and exchange rate fluctuations continuing to affect corporate performance.

Dian Diagnostics released its 2026 interim report, with net profit attributable to the parent company of 232 million yuan, up 2160.87% from the same period last year. Total operating revenue was 4.773 billion yuan, down 3.30% year-on-year. Net cash inflow from operating activities was 259 million yuan, down 6.59% year-on-year. The latest asset-liability ratio was 37.97%, down 5.04 percentage points from the same period last year. Gross margin was 30.12%, rising for two consecutive quarters. Diluted earnings per share were 0.38 yuan, up 2163.10% year-on-year.

Tuojing Technology achieved operating revenue of 2.913 billion yuan in the first half of 2026, up 49.06% year on year, with net profit attributable to shareholders of the listed company at 1.343 billion yuan, a surge of 1324.1%. The company also plans to distribute a cash dividend of 3.5 yuan for every 10 shares to all shareholders. Dian Diagnostics posted first-half net profit of 232 million yuan, up 2160.87% year on year; Rike Chemical's net profit was 30.27 million yuan, up 2518.58%. Ping An Insurance achieved net profit attributable to shareholders of the parent company of 92.585 billion yuan in the first half, up 36.1% year on year. Jiangsu Expressway plans to acquire a 100% stake in Suzhou-Wuxi-Changzhou Southern Expressway Company for 7.341 billion yuan in cash. Shenzhen Keda said its storage equipment business made a breakthrough, securing new orders of about 57.926 million yuan from a well-known North American HDD storage manufacturer in the first half.